- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07537413
Ceftriaxon-dosering for ikke-kritisk samfunnservervet lungebetennelse (DC-CAP)
Pragmatisk randomisert studie som evaluerer dosering av Ceftriaxon for samfunnservervet lungebetennelse utenfor intensivavdelingen
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.<p>
Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This study will be a pragmatic trial in which prospectively enrolled patients will be randomly assigned to Ceftriaxone dosed either 1 gram or 2 grams daily. When a clinician in the emergency department or non-intensive care inpatient ward orders Ceftriaxone and selects 'community-acquired pneumonia' as the indication, the electronic health record software used at the study sites (Epic) will prompt the ordering clinician to opt into the study. No direct patient contact will occur.
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: Jonathan D Baghdadi, MD, PhD
- Telefonnummer: 410-706-0066
- E-post: jbaghdadi@som.umaryland.edu
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- University of Maryland Medical Center
-
Ta kontakt med:
- Megan Dunning, MD
- Telefonnummer: 410-328-8667
- E-post: mdunning@ihv.umaryland.edu
-
Baltimore, Maryland, Forente stater, 21201
- University of Maryland Medical Center - Midtown Campus
-
Ta kontakt med:
- Jonathan Baghdadi, MD, PhD
- Telefonnummer: 410-225-8000
- E-post: jbaghdadi@som.umaryland.edu
-
Glen Burnie, Maryland, Forente stater, 21061
- UM Baltimore Washington Medical Center
-
Ta kontakt med:
- Stephanie Pires, PharmD
- Telefonnummer: 410-787-4000
- E-post: Stephanie.Pires@umm.edu
-
Towson, Maryland, Forente stater, 21204
- University of Maryland St. Joseph Medical Center
-
Ta kontakt med:
- Rose Kohinke, PharmD
- Telefonnummer: 410-337-1000
- E-post: Rose.Kohinke@umm.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Evaluated in the emergency department or within 72 hours of hospitalization
- Prescribed Ceftriaxone for community-acquired pneumonia
Exclusion Criteria:
- Planned or present admission to an intensive care unit
- Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Low Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of non-critical community-acquired pneumonia. |
|
Aktiv komparator: Moderate Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 2 grams daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed at 2 grams daily per institutional guidance for treatment of community-acquired pneumonia. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antibiotic escalation within 5 days of randomization
Tidsramme: The outcome will be assessed 5 days after enrollment
|
Defined by increasing the dose or frequency of Ceftriaxone, starting additional antibiotics not ordered concurrently with Ceftriaxone, or switching Ceftriaxone to an antibiotic with a broader spectrum up activity >24 hours after enrollment; antibiotic changes made on the calendar day of discharge in preparation for discharge alive from the hospital will not be considered escalation |
The outcome will be assessed 5 days after enrollment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to stability
Tidsramme: The outcome will be assessed 90 days after enrollment
|
Time in days from randomization until stability defined by temperature < 38, heart rate < 100, respiratory rate < 24, oxygen saturation > 90%, systolic blood pressure ≥ 90, and return to baseline mental status based on Glasgow Coma Score over a 24-hour period |
The outcome will be assessed 90 days after enrollment
|
|
Clinical deterioration within 10 days of randomization
Tidsramme: The outcome will be assessed 10 days after enrollment
|
Defined by admission to an intensive care unit, mechanical ventilation, or in-hospital mortality on any hospital day, or supplemental oxygen >5 L after hospital day 3 during the index encounter |
The outcome will be assessed 10 days after enrollment
|
|
Ceftriaxone-associated toxicity within 10 days of randomization
Tidsramme: The outcome will be assessed 10 days after enrollment
|
Defined by new development of Hemoglobin < 10, elevated liver enzymes or or total bilirubin, clinically significant diarrhea (represented by Clostridioides difficile testing), or rash (represented by consult to dermatology) |
The outcome will be assessed 10 days after enrollment
|
|
Ranked composite outcome
Tidsramme: The outcome will be assessed 30 days after enrollment
|
Rank 1 (highest rank) = no antibiotic escalation, clinical deterioration, or Ceftriaxone-associated toxicity Rank 2 = antibiotic escalation without clinical deterioration or Ceftriaxone-associated toxicity Rank 3 = Ceftriaxone-associated toxicity without clinical deterioration Rank 4 = clinical deterioration without 30-day mortality Rank 5 = 30-day mortality |
The outcome will be assessed 30 days after enrollment
|
|
Duration of antibiotics
Tidsramme: The outcome will be assessed 90 days after enrollment
|
Defined as the total days of antibiotic therapy during the hospital encounter |
The outcome will be assessed 90 days after enrollment
|
|
Hospital length of stay
Tidsramme: The outcome will be assessed 90 days after enrollment
|
Duration of hospitalization in days |
The outcome will be assessed 90 days after enrollment
|
|
All-cause readmission
Tidsramme: The outcome will be assessed 90 days from enrollment
|
Readmission for any reason within 30 days of hospital discharge |
The outcome will be assessed 90 days from enrollment
|
|
In-hospital mortality
Tidsramme: The outcome will be assessed 90 days after enrollment
|
In-hospital death or discharge to hospice |
The outcome will be assessed 90 days after enrollment
|
|
Clostridioides difficile infection
Tidsramme: The outcome will be assessed 90 days after enrollment
|
Positive laboratory test for Clostridioides difficile within 30 days of randomization |
The outcome will be assessed 90 days after enrollment
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HP-00117776
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .